ALX Oncology Holdings Inc.
06/11/2026 | Press release | Distributed by Public on 06/11/2026 14:02
Proxy Results (Form 8-K)
Item 5.07 Submission of matters to a vote of security holders.
ALX Oncology Holdings Inc. (the "Company") held its Annual Meeting of stockholders (the "Annual Meeting") on June 10, 2026. The matters voted upon at the Annual Meeting and the voting results for each proposal are set forth below.
Proposal 1: Election of Two Class II Directors
|
Name of Director |
For |
Withheld |
Broker Non-Votes |
|||||||||
|
Daniel Curran, M.D. |
100,933,233 |
57,798 |
18,313,833 |
|||||||||
|
Rekha Hemrajani |
82,732,430 |
18,258,601 |
18,313,833 |
|||||||||
|
Chris Takimoto, M.D., Ph.D., F.A.C.P. |
100,946,696 |
44,335 |
18,313,833 |
|||||||||
Each director nominee was duly elected to serve until the 2029 annual meeting of stockholders and until their successor is duly elected and qualified, subject to earlier resignation or removal.
Proposal 2: Advisory Vote on the Compensation of the Company's Named Executive Officers
|
For |
Against |
Abstain |
Broker Non-Votes |
|||||||||||
|
84,540,061 |
13,497,711 |
2,953,259 |
18,313,833 |
|||||||||||
The stockholders approved, on an advisory basis, the compensation paid to the Company's named executive officers, as disclosed in the proxy statement for the Annual Meeting.
Proposal 3: Ratification of the Appointment of Independent Registered Public Accounting Firm
|
For |
Against |
Abstain |
||||||||
|
119,293,775 |
1,797 |
9,292 |
||||||||
The stockholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.
ALX Oncology Holdings Inc. published this content on June 11, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on June 11, 2026 at 20:02 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]